阿帕替尼治疗晚期胃癌伴肝转移患者的效果观察及其对免疫功能及肿瘤血管生长因子的影响  

Observation of the effect of apatinib in the treatment of patients with advanced gastric cancer with liver metastasis and its effect on immune function and tumor vascular growth factor

作　　者：牛红卫 张秀娟 张军峰 Niu Hongwei;Zhang Xiujuan;Zhang Junfeng(Department of Oncology,Hebi People′s Hospital,Henan 458030,China;不详)

机构地区：[1]河南省鹤壁市人民医院肿瘤科,458030 [2]河南省鹤壁市人民医院药剂科,458030

出　　处：《山西医药杂志》2022年第10期1105-1108,共4页Shanxi Medical Journal

摘　　要：目的 探讨阿帕替尼治疗晚期胃癌伴肝转移的效果及对免疫功能、肿瘤血管生长因子的影响。方法 按照治疗方案不同将我院123例晚期胃癌伴肝转移患者分为2组,对照组61例给予多西他赛和替吉奥化疗,观察组62例在对照组基础上予以阿帕替尼治疗,观察2组血清肿瘤标志物水平、免疫功能、肿瘤血管内皮因子水平以及不良反应发生率。结果 治疗后,观察组癌胚抗原(CEA)、糖类抗原(CA)125、CA724、CA242、CA199水平均低于对照组,CD3^(+)、CD4^(+)高于对照组,CD8^(+)低于对照组(P<0.05);观察组血管内皮生长因子(VEGF)、肿瘤特异性生长因子(TSGF)、基质金属蛋白酶(MMP)-9、MMP-2水平均低于对照组(P<0.05),2组不良反应总发生率对比差异无统计学意义(P>0.05)。结论 阿帕替尼用于晚期胃癌伴肝转移患者中可调节免疫功能和肿瘤血管内皮因子水平,降低肿瘤标志物水平且不增加不良反应发生率。Objective To investigate the effect of apatinib in the treatment of advanced gastric cancer with liver metastasis and the effect of apatinib on immune function and tumor vascular growth factor. Methods A total of 123petients with advanced gastric cancer with liver metastasis in our hospital were divided into two groups according to different treatment plans. The control group(n=61) received docetaxel and diageo chemotherapy and the observation group was treated with apatinib on the basis of control group(n=62). The serum tumor markers, immune function and tumor endothelial factor levels and the incidence of adverse reactions of the two group were observed. Results After treatment, carcinoma embryonic antigen(CEA), carbohydrate antigen(CA) 125, CA724, CA242 and CA199 in observation group were lower than those in control group, CD3^(+)and CD4^(+)T cells in observation group were higher than those in control group, while CD8^(+)T cells were lower than that in control group(P<0.05). The levels of vascular endothelial growth factor(VEGF), tumor specificity growth factor(TSGF), matrix metalloproteinase(MMP)-9 and MMP-2 in the observation group were lower than those in the control group(P<0.05), and there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Apatinib can be used in patients with advanced gastric cancer with liver metastasis by regulating the immune function and tumor vascular endothelial factor levels, reducing the level of tumor markers without increasing the incidence of adverse reactions.

关 键 词：胃肿瘤 肿瘤转移 阿帕替尼 免疫功能 生长因子 

分 类 号：R735.2[医药卫生—肿瘤]